نتایج جستجو برای: fulvestrant

تعداد نتایج: 782  

2016
Ameya Paranjpe Nathan I. Bailey Santhi Konduri George C. Bobustuc Francis Ali-Osman Mohd. A. Yusuf Surendra R. Punganuru Hanumantha Rao Madala Debasish Basak AGM Mostofa Kalkunte S. Srivenugopal

Endocrine therapy using estrogen receptor-α (ER-α) antagonists for attenuating horm2one-driven cell proliferation is a major treatment modality for breast cancers. To exploit any DNA repair deficiencies associated with endocrine therapy, we investigated the functional and physical interactions of ER-α with O6-methylguanine DNA methyltransferase (MGMT), a unique DNA repair protein that confers t...

2017
Ricardo L.B. Costa William J. Gradishar

Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer death amongAsianwomen.Hormonal receptor (HR) –positive tumors are the most common type of breast cancer, and treatment of metastatic disease remains palliative. Endocrine therapy is the cornerstone of treatment of patients with HRpositive metastatic breast cancer (MBC). In postmenopausal patients, aroma...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2013
F Zagouri T N Sergentanis D Chrysikos E Zografos M Rudas G Steger G Zografos R Bartsch

women with HER2 positive MBC. Proc Am Soc Clin Oncol 2003; 22: (Abstr 294). 3. Fyfe GA, Mass R, Murphy M et al. Survival benefit of trastuzumab (Herceptin) and chemotherapy in older (age >60) patients. Proc Am Soc Clin Oncol 2001; 20: (Abstr 189). 4. Serrano C, Cortés J, De Mattos-Arruda L et al. Trastuzumab related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Onco...

Journal: :Endocrine-related cancer 2015
Penn Muluhngwi Carolyn M Klinge

Therapies targeting estrogen receptor alpha (ERα), including selective ER modulators such as tamoxifen, selective ER downregulators such as fulvestrant (ICI 182 780), and aromatase inhibitors such as letrozole, are successfully used in treating breast cancer patients whose initial tumor expresses ERα. Unfortunately, the effectiveness of endocrine therapies is limited by acquired resistance. The...

Journal: :Nuclear Receptor Signaling 2006
Mathilde Calligé Hélène Richard-Foy

In this perspective we consider new aspects of ligand-induced estrogen receptor alpha (ERalpha) degradation. What are the possible roles of CSN5/Jab1 and the CSN complex in this process? We compare hormone (estrogen) or pure antagonist (fulvestrant) induced degradation of ERalpha and review the effects of kinase-inhibitors and CRM1-dependent nuclear export on ERalpha degradation and transcripti...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید